NCT01536145 - CP-751,871 Treatment For Patients With Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions

Multiple Myeloma

Interventions

DRUG

CP-751,871

CP-751,871 was given at doses ranging from 0.025 mg/kg up to 20 mg/kg IV every 4 weeks until disease progression or lack of tolerability

Trial Locations (6)

Pfizer Investigational Site, Tampa

Pfizer Investigational Site, Rochester

Pfizer Investigational Site, Phoenix

Pfizer Investigational Site, Scottsdale

Pfizer Investigational Site, Boston

Pfizer Investigational Site, New York